Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Gastroparesis Updates on Pathogenesis and Management

  • Liu, Nanlong (Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville) ;
  • Abell, Thomas (Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville)
  • Received : 2016.07.06
  • Accepted : 2016.09.09
  • Published : 2017.09.15
⟨ Previous Next ⟩

Abstract

Gastroparesis (Gp) is a chronic disease that presents with clinical symptoms of early satiety, bloating, nausea, vomiting, and abdominal pain. Along with these symptoms, an objective finding of delayed gastric emptying, along with a documented absence of gastric outlet obstruction, are required for diagnosis. This article focuses on updates in the pathogenesis and management of Gp. Recent studies on full thickness biopsies of Gp patients have shed light on the complex interactions of the central, autonomic, and enteric nervous systems, which all play key roles in maintaining normal gut motility. The management of Gp has evolved beyond prokinetics and antiemetics with the use of gastric electrical stimulators (GES). In addition, this review aims to introduce the concept of gastroparesis-like syndrome (GLS). GLS helps groups of patients who have the cardinal symptoms of Gp but have a normal or rapid emptying test. Recent tests have shown that patients with Gp and GLS have similar pathophysiology, benefit greatly from GES placement, and likely should be treated in a similar manner.

Keywords

References

  1. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37. https://doi.org/10.1038/ajg.2012.373
  2. Cherian D, Parkman HP. Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterol Motil 2012;24:217-222.e103. https://doi.org/10.1111/j.1365-2982.2011.01828.x
  3. Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clin Gastroenterol Hepatol 2010;8:676-681. https://doi.org/10.1016/j.cgh.2010.04.027
  4. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009; 136:1225-1233. https://doi.org/10.1053/j.gastro.2008.12.047
  5. Hyett B, Martinez FJ, Gill BM, et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 2009;137:445-452. https://doi.org/10.1053/j.gastro.2009.04.055
  6. Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis--clinical characteristics and long-term outcomes. Am J Gastroenterol 1997;92:1501-1504.
  7. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012; 107:82-88. https://doi.org/10.1038/ajg.2011.310
  8. Frantzides CT, Carlson MA, Zografakis JG, Moore RE, Zeni T, Madan AK. Postoperative gastrointestinal complaints after laparoscopic Nissen fundoplication. JSLS 2006;10:39-42.
  9. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol 2008;36:44-54. https://doi.org/10.2967/jnmt.107.048116
  10. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther 2008;27:186-196.
  11. Bruno G, Lopetuso LR, Ianiro G, et al. 13C-octanoic acid breath test to study gastric emptying time. Eur Rev Med Pharmacol Sci 2013;17 Suppl 2:59-64.
  12. Maes BD, Ghoos YF, Geypens BJ, et al. Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med 1994;35:824-831.
  13. Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 2011;9:567-576.e4. https://doi.org/10.1016/j.cgh.2011.03.003
  14. Bashashati M, McCallum RW. Motility: is 'ICC-opathy' present in gastroparesis-like syndrome? Nat Rev Gastroenterol Hepatol 2015;12:375-376. https://doi.org/10.1038/nrgastro.2015.96
  15. Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003;18:141-150. https://doi.org/10.1046/j.1365-2036.2003.01612.x
  16. Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 2011;9:5-12. https://doi.org/10.1016/j.cgh.2010.09.022
  17. Oh JH, Pasricha PJ. Recent advances in the pathophysiology and treatment of gastroparesis. J Neurogastroenterol Motil 2013;19:18-24. https://doi.org/10.5056/jnm.2013.19.1.18
  18. Angeli TR, Cheng LK, Du P, et al. Loss of interstitial cells of Cajal and patterns of gastric dysrhythmia in patients with chronic unexplained nausea and vomiting. Gastroenterology 2015;149:56-66.e5. https://doi.org/10.1053/j.gastro.2015.04.003
  19. Farrugia G. Interstitial cells of Cajal in health and disease. Neurogastroenterol Motil 2008;20 Suppl 1:54-63. https://doi.org/10.1111/j.1365-2982.2008.01109.x
  20. Grover M, Bernard CE, Pasricha PJ, et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil 2012;24:531-539.e249. https://doi.org/10.1111/j.1365-2982.2012.01894.x
  21. Vittal H, Farrugia G, Gomez G, Pasricha PJ. Mechanisms of disease: the pathological basis of gastroparesis: a review of experimental and clinical studies. Nat Clin Pract Gastroenterol Hepatol 2007;4:336-346.
  22. Orihata M, Sarna SK. Inhibition of nitric oxide synthase delays gastric emptying of solid meals. J Pharmacol Exp Ther 1994;271:660-670.
  23. Plourde V, Quintero E, Suto G, Coimbra C, Tache Y. Delayed gastric emptying induced by inhibitors of nitric oxide synthase in rats. Eur J Pharmacol 1994;256:125-129. https://doi.org/10.1016/0014-2999(94)90236-4
  24. Takahashi T, Nakamura K, Itoh H, Sima AA, Owyang C. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 1997;113:1535-1544. https://doi.org/10.1053/gast.1997.v113.pm9352855
  25. Wrzos HF, Cruz A, Polavarapu R, Shearer D, Ouyang A. Nitric oxide synthase (NOS) expression in the myenteric plexus of streptozotocin-diabetic rats. Dig Dis Sci 1997;42:2106-2110. https://doi.org/10.1023/A:1018830820537
  26. Sarker S, Ahmad N, Kedar A, et al. T2063 Inflammatory and hematologic disorders are associated with GI symptoms in diabetic gastroparesis. Gastroenterology 2010;138(5 Supple 1):S-624.
  27. Harberson J, Thomas RM, Harbison SP, Parkman HP. Gastric neuromuscular pathology in gastroparesis: analysis of full-thickness antral biopsies. Dig Dis Sci 2010;55:359-370. https://doi.org/10.1007/s10620-009-1071-2
  28. Soota K, Kedar A, Nikitina Y, Arendale E, Vedanarayanan V, Abell TL. Immunomodulation for treatment of drug and device refractory gastroparesis. Results Immunol 2016;6:11-14. https://doi.org/10.1016/j.rinim.2016.02.001
  29. Flanagan EP, Saito YA, Lennon VA, et al. Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility. Neurogastroenterol Motil 2014;26:1285-1297. https://doi.org/10.1111/nmo.12391
  30. Zarate N, Mearin F, Wang XY, Hewlett B, Huizinga JD, Malagelada JR. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut 2003;52:966-970. https://doi.org/10.1136/gut.52.7.966
  31. Stocker A, Abell TL, Rashed H, Kedar A, Boatright B, Chen J. Autonomic evaluation of patients with gastroparesis and neurostimulation: comparisons of direct/systemic and indirect/cardiac measures. Gastroenterology Res 2016;9:10-16. https://doi.org/10.14740/gr667w
  32. Qin C, Sun Y, Chen JD, Foreman RD. Gastric electrical stimulation modulates neuronal activity in nucleus tractus solitarii in rats. Auton Neurosci 2005;119:1-8. https://doi.org/10.1016/j.autneu.2005.01.007
  33. Cutts T, Holmes S, Kedar A, Beatty K, K Mohammad M, Abell T. Twenty-five years of advocacy for patients with gastroparesis: support group therapy and patient reported outcome tool development. BMC Gastroenterol 2016;16:107. https://doi.org/10.1186/s12876-016-0523-3
  34. Kedar A, McElmurray L, Abell TL. Sa1332 Bloating and abdominal pain symptoms may be important indicators of disease status in patients with severe dyspepsia or gastroparesis. Gastroenterology 2014;146(5 Supple 1):S-265.
  35. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006;18:263-283. https://doi.org/10.1111/j.1365-2982.2006.00760.x
  36. Bouras EP, Scolapio JS. Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol 2004;38:549-557. https://doi.org/10.1097/00004836-200408000-00003
  37. Parrish CR, Yoshida CM. Nutrition intervention for the patient with gastroparesis: an update. Pract Gastroenterol 2005;29:29-66.
  38. Sanaka M, Anjiki H, Tsutsumi H, et al. Effect of cigarette smoking on gastric emptying of solids in Japanese smokers: a crossover study using the 13C-octanoic acid breath test. J Gastroenterol 2005;40:578-582. https://doi.org/10.1007/s00535-005-1591-2
  39. Pfeiffer A, Hogl B, Kaess H. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin Investig 1992;70:487-491.
  40. Camilleri M. Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. Am J Gastroenterol 1994;89:1769-1774.
  41. Maple JT, Petersen BT, Baron TH, Gostout CJ, Wong Kee Song LM, Buttar NS. Direct percutaneous endoscopic jejunostomy: outcomes in 307 consecutive attempts. Am J Gastroenterol 2005;100:2681-2688. https://doi.org/10.1111/j.1572-0241.2005.00334.x
  42. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996;91:2174-2178.
  43. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592-1622. https://doi.org/10.1053/j.gastro.2004.09.055
  44. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:675-680. https://doi.org/10.1007/BF00400569
  45. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002;97:604-611. https://doi.org/10.1111/j.1572-0241.2002.05537.x
  46. Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997;113:60-66. https://doi.org/10.1016/S0016-5085(97)70080-5
  47. Jones KL, Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentration influences postprandial fullness in IDDM. Diabetes Care 1997;20:1141-1146. https://doi.org/10.2337/diacare.20.7.1141
  48. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6:463-467. https://doi.org/10.2337/diacare.6.5.463
  49. Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 1982;96:444-446. https://doi.org/10.7326/0003-4819-96-4-444
  50. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999;60:422-427. https://doi.org/10.1159/000007687
  51. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153:1469-1475. https://doi.org/10.1001/archinte.1993.00410120051007
  52. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) 1985;291:930-932. https://doi.org/10.1136/bmj.291.6500.930
  53. Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997;12:952-957. https://doi.org/10.1002/mds.870120618
  54. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230-1234.
  55. Basque JR, Kikuchi Y, Ohtsubo T, Sarashina G, Nakamura H. Efficacy of itopride hydrochloride on gastric emptying in patients with diabetic gastroparesis. Am J Gastroenterol 2005;100:S325.
  56. Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-746. https://doi.org/10.1136/gut.2007.132449
  57. Stevens JE, Russo A, Maddox AF, et al. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil 2008;20:456-463. https://doi.org/10.1111/j.1365-2982.2007.01058.x
  58. Weber FH Jr, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993;88:485-490.
  59. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:1511-1514. https://doi.org/10.2337/diacare.16.11.1511
  60. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203-207.
  61. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990;322:1028-1031. https://doi.org/10.1056/NEJM199004123221502
  62. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 2010;16:407-413. https://doi.org/10.5056/jnm.2010.16.4.407
  63. Potter TG, Snider KR. Azithromycin for the treatment of gastroparesis. Ann Pharmacother 2013;47:411-415. https://doi.org/10.1345/aph.1R541
  64. Chini P, Toskes PP, Waseem S, Hou W, McDonald R, Moshiree B. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol 2012;47:422-427. https://doi.org/10.3109/00365521.2012.654402
  65. Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010;55:675-683. https://doi.org/10.1007/s10620-009-1038-3
  66. McCallum RW, Cynshi O; Investigative Team. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis: a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther 2007;26:1121-1130. https://doi.org/10.1111/j.1365-2036.2007.03461.x
  67. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept 2009;155:18-23. https://doi.org/10.1016/j.regpep.2009.03.011
  68. McCallum RW, Cynshi O; US Investigative Team. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007;26:107-116. https://doi.org/10.1111/j.1365-2036.2007.03346.x
  69. Fang J, McCallum R, DiBase J, Schmitt C, Kipnes M. Effect of mitemcinal fumarate (GM-611) on gastric emptying in patients with idiopathic or diabetic gastroparesis. Gastroenterology 2004;126(4 Suppl 2):A483.
  70. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653-1661. https://doi.org/10.1046/j.1365-2036.2000.00868.x
  71. Fraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis: effects of cisapride. Gut 1994;35:172-178. https://doi.org/10.1136/gut.35.2.172
  72. Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987;28:300-305. https://doi.org/10.1136/gut.28.3.300
  73. Richards RD, Valenzuela GA, Davenport KG, Fisher KL, McCallum RW. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993;38:811-816. https://doi.org/10.1007/BF01295905
  74. Banh HL, MacLean C, Topp T, Hall R. The use of tegaserod in critically ill patients with impaired gastric motility. Clin Pharmacol Ther 2005;77:583-586. https://doi.org/10.1016/j.clpt.2005.02.002
  75. Crowell MD, Mathis C, Schettler VA, Yunus T, Lacy BE. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol Motil 2005;17:738-743. https://doi.org/10.1111/j.1365-2982.2005.00681.x
  76. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-909. https://doi.org/10.1056/NEJM198110153051601
  77. Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol 1999;94:2855-2860. https://doi.org/10.1111/j.1572-0241.1999.01428.x
  78. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci 2007;52:418-424. https://doi.org/10.1007/s10620-006-9378-8
  79. Abell TL, Van Cutsem E, Abrahamsson H, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002;66:204-212. https://doi.org/10.1159/000068359
  80. McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 2011;9: 314-319.e1. https://doi.org/10.1016/j.cgh.2010.12.013
  81. Cutts TF, Luo J, Starkebaum W, Rashed H, Abell TL. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil 2005;17:35-43. https://doi.org/10.1111/j.1365-2982.2004.00609.x
  82. Singh S, McCrary J, Kedar A, et al. Temporary endoscopic stimulation in gastroparesis-like syndrome. J Neurogastroenterol Motil 2015;21:520-527. https://doi.org/10.5056/jnm15046
  83. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003;98:2122-2129. https://doi.org/10.1111/j.1572-0241.2003.07721.x
  84. Hibbard ML, Dunst CM, Swanstrom LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg 2011;15:1513-1519. https://doi.org/10.1007/s11605-011-1607-6

Cited by

  1. Gastric Peroral Endoscopic Myotomy (G-POEM) as a Treatment for Refractory Gastroparesis: Long-Term Outcomes vol.2018, pp.None, 2017, https://doi.org/10.1155/2018/6409698
  2. Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists vol.8, pp.5, 2017, https://doi.org/10.2217/nmt-2018-0020
  3. Efficacy of Gastric Electrical Stimulation for Gastroparesis: US/European Comparison vol.11, pp.5, 2017, https://doi.org/10.14740/gr1061w
  4. Hybrid endoluminal stapled pyloroplasty: an alternative treatment option for gastric outlet obstruction syndrome vol.33, pp.1, 2017, https://doi.org/10.1007/s00464-018-6493-5
  5. Upper Gastrointestinal Manifestation of Bezoars and the Etiological Factors: A Literature Review vol.2019, pp.None, 2017, https://doi.org/10.1155/2019/5698532
  6. Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment vol.25, pp.1, 2017, https://doi.org/10.5056/jnm18162
  7. Gastrointestinal Malabsorption of Thyroxine vol.40, pp.1, 2017, https://doi.org/10.1210/er.2018-00168
  8. Gastroparesis and Dumping Syndrome: Current Concepts and Management vol.8, pp.8, 2017, https://doi.org/10.3390/jcm8081127
  9. Mirtazapine for Refractory Gastroparesis vol.6, pp.10, 2017, https://doi.org/10.14309/crj.0000000000000256
  10. Gastroparesis: New insights into an old disease vol.26, pp.19, 2017, https://doi.org/10.3748/wjg.v26.i19.2332
  11. Minimally Invasive Gastric Electrical Stimulation Using a Newly Developed Wireless Gastrostimulator: A Pilot Animal Study vol.26, pp.3, 2017, https://doi.org/10.5056/jnm20063
  12. Toward an Improved Treatment for Gastroparesis vol.26, pp.3, 2017, https://doi.org/10.5056/jnm20129
  13. Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis vol.14, pp.5, 2017, https://doi.org/10.5009/gnl19103
  14. Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility vol.9, pp.None, 2021, https://doi.org/10.1177/20503121211000909
  15. Medication-Induced Gastroparesis: A Case Report vol.9, pp.None, 2021, https://doi.org/10.1177/23247096211051919
  16. Knowledge, Attitude, and Practice Survey of Gastroparesis in Asia by Asian Neurogastroenterology and Motility Association vol.27, pp.1, 2017, https://doi.org/10.5056/jnm20117
  17. Gastric Electrical Stimulation for Treatment of Refractory Gastroparesis: the Current Approach to Management vol.23, pp.2, 2017, https://doi.org/10.1007/s11894-020-00803-0
  18. Gastroparesis in the Hospital Setting vol.36, pp.1, 2017, https://doi.org/10.1002/ncp.10611
  19. Medical and surgical management of gastroparesis: a systematic review vol.17, pp.4, 2021, https://doi.org/10.1016/j.soard.2020.10.027
  20. Dysphagia, reflux and related sequelae due to altered physiology in scleroderma vol.27, pp.31, 2017, https://doi.org/10.3748/wjg.v27.i31.5201
  21. Anatomical evaluation of the esophagus using computed tomography to predict acute gastroparesis following atrial fibrillation ablation vol.37, pp.5, 2017, https://doi.org/10.1002/joa3.12625
  22. 만성 오심 구토 증후군 환자의 한의치료 1례 vol.42, pp.5, 2021, https://doi.org/10.22246/jikm.2021.42.5.967
  23. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study vol.13, pp.12, 2021, https://doi.org/10.3390/nu13124298